| Budenofalk (budesonide gastro-resistant) / Dr Falk |
| Completed | 3 | 343 | Europe | budesonide, Budenofalk 3mg capsules, mesalazine, Salofalk 1000mg granules | Dr. Falk Pharma GmbH | Colitis, Ulcerative | 08/08 | 08/10 | | |
| Completed | 3 | 92 | Europe | Budesonide, Budenofalk 3mg capsules, Placebo | Dr. Falk Pharma GmbH, The Swedish Organization for Studies on Inflammatory Bowel Disease | Induction and Maintaining Remission of Collagenous Colitis | 03/13 | 09/13 | | |
2016-001921-15: Novel budesonide suppository vs. budesonide foam in acute ulcerative proctitis. |
|
|
| Ongoing | 3 | 576 | Europe | Budenofalk® suppositories (BUS), Budenofalk® 2 mg foam, Suppository, Rectal foam, Budenofalk® 2 mg foam | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Acute Ulcerative Proctitis, Acute Ulcerative Proctitis - Inflammation of the Rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |
2019-003334-16: Novel budenosid suppository in addition to basic therapy with oral mesalazine compared to basic therapy alone for treatment of ulcerative colitis |
|
|
| Not yet recruiting | 3 | 360 | Europe, RoW | Budenofalk® suppositories, Salofalk 3g gastro-resistant prolonged-release granules, Suppository, Gastro-resistant granules, Salofalk 3g gastro-resistant prolonged-release granules | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | acute ulcerative colitis, acute ulcerative colitis - inflammation and ulcers of the colon and rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT04921033: Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease |
|
|
| Recruiting | 3 | 256 | RoW | EEN (Nestle Modulen®), Standart of care, Budesonide (Budenofalk®), Prednisolone (Deltacortril®), Azathioprine (Imuran®) | Duzce University | Crohn Disease, Nutrient; Excess, Remission/Regression | 01/26 | 01/26 | | |
